WHAT THIS PAPER ADDS This is the largest study of outcomes after lower limb bypass in patients with end-stage renal failure. Cumulative mortality was 49.6% at 2 years. Freedom from major adverse limb events was 77.4%, and freedom from amputation was 85.0%. Additionally, a multi-regression analysis revealed that an ejection fraction <40%, a serum albumin level <3.0 g/dL, and non-ambulatory status were independent predictors of a poor outcome.
INTRODUCTION
Critical limb ischaemia (CLI) is a limb threatening condition that requires revascularisation to relieve ischaemic pain, heal ischaemic ulcers, prevent limb loss, and preserve ambulatory status and quality of life. Patients with CLI who do not undergo arterial revascularisation have mortality and amputation rates as high as 54% and 46%, respectively, after 12 months. 1 In contrast, patients with CLI who undergo successful revascularisation survive longer and have an improved quality of life compared with patients who only receive medical treatment or who undergo primary amputation. 2 Surgical bypass with an autogenous vein represents the gold standard for CLI treatment, with numerous reports documenting graft and limb related outcomes. Recently, the application of endovascular therapy (EVT) to treat CLI has increased, and this technique is particularly attractive for patients at increased risk for surgery. In fact, certain studies have advocated the preferential use of EVT as an initial approach in CLI. 3, 4 However, the first line treatment for revascularisation in CLI remains controversial. The Trans-Atlantic Inter-Society Consensus (TASC) recommends that the profile and extent of arterial lesions should be used to select EVT or bypass surgery, whereas the 'Bypass versus Angioplasty in Severe Ischaemia of the Leg' (BASIL) trial group suggests that life expectancy >2 years and good vein quality are better served by selecting autogenous vein bypass surgery as the initial treatment. 2, 5 In general, the combination of CLI and dialysis dependent end-stage renal disease (ESRD) has been associated with poor medium and long-term survival. 6 Therefore, careful selection of patients for surgery is essential. However, a few small to medium sized studies have addressed infrainguinal bypass grafting (IBG) in patients with ESRD. Moreover, little information is available regarding the predictors of short and medium-term outcomes after IBG in patients receiving haemodialysis.
The aims of this study were to assess, at a single institution in Japan, the short and medium-term outcomes of IBG in patients with ESRD and to identify the preoperative factors that may be predictive of 30 day mortality, amputation free survival (AFS), freedom from major adverse limb events (MALE), limb salvage, and survival.
METHODS

Study design
This clinical investigation was undertaken to compare the pre-operative medical risk factors with the outcomes of consecutive patients with ESRD on haemodialysis who had undergone de novo IBG to treat CLI at the Kokura Memorial Hospital. Approval for this project was obtained from the hospital's institutional review board. A retrospective assessment was performed for each patient, and the data were statistically analysed to identify prognostic factors of short and medium-term clinical outcomes.
Patients
Consecutive patients with critically ischaemic limbs and peripheral arterial disease who had undergone de novo infrainguinal revascularisation at the authors' hospital from April 2007 to March 2011 were analysed retrospectively. All of the patients were symptomatic (Fontaine classification III [rest pain] or IV [tissue loss/gangrene] and Rutherford categories 4e6), with threatened limb loss. We excluded patients with CLI that was attributable to acute arterial occlusion or to either non-atherosclerotic or inflammatory disease.
During the study period, IBG was performed in 162 patients (198 limbs), EVT in 221 (260 limbs), and primary amputation in 21 patients (21 limbs). Among these patients, 186 (229 limbs) with ESRD presented with CLI. The patients' laboratory tests, cardiovascular function (peripheral angiography, electrocardiography, coronary angiography, and echocardiography), respiratory function, and other parameters were examined routinely. Each case was also discussed with interventional cardiologists, and the decision was made over which procedure, whether EVT or bypass, would be the first line treatment depending on general condition and lower limb severity. Primary amputation was performed in patients with severe dementia or long-term bedridden status due to neurogenic deficits, extensive infection above the ankle, or refusal of revascularisation. Ultimately, of the 186 patients, 117 (140 limbs) underwent EVT and nine patients (9 limbs) underwent primary amputation.
IBG was performed in 89 dialysis dependent patients (112 limbs). Of the patients who underwent IBG, 29 (32 limbs) experienced the endovascular-first approach. Of these, six patients (six limbs) underwent IBG after failed angioplasty, and the others were cases in which angiographic technical success (one straight line to the foot) was obtained, but wound healing was not, so IBG was then performed. The cases of these patients were reviewed and clarification of their clinical outcomes was attempted.
Revascularisation procedure and follow-up
All of the infrainguinal bypasses in the patients with CLI were performed using vein grafts. The distal anastomotic site was chosen based on the optimal run-off vessel to the diseased toe. Proximal anastomoses were performed with 6-0 polypropylene sutures, and distal anastomoses were performed with 7-0 or 8-0 polypropylene sutures. For distal anastomoses, the non-dissection method with pneumatic tourniquets to control blood flow was used. The greater saphenous vein was used as a first choice conduit if its diameter was >2 mm, as determined preoperatively by a duplex scan in the standing position. If this vein was not accessible, the lesser saphenous vein or an arm vein was used. If the single saphenous vein was too short, a spliced vein graft was created with 7-0 polypropylene sutures. Upon completion of the anastomoses, angiography was performed to check for graft stenosis and anastomotic site problems. Moreover, graft flow was assessed by ultrasonography using a linear transducer. The measurements were obtained using a transit time flowmeter (300-Series Flowmeter; Transonic Systems Inc., NY, USA). More specifically, a pre-calibrated probe of a size that fitted the graft (from 3e4 mm) was placed around the vein graft. This procedure was performed after the completion of IBG. Additionally, heparin was infused for 24 hours, and prostaglandin E1 was infused for several days postoperatively. Antiplatelet drugs were also administered to every patient.
Routine follow up consisted of post-operative visits every month for 3 months, followed by visits at 3 month intervals for 2 years and at 6 month intervals thereafter. Routine surveillance included ankle-brachial index (ABI), skin perfusion pressure (SPP), and duplex ultrasound (US) measurements. Duplex scanning of the graft was the primary method for detecting occult graft lesions. A focal increase in graft velocity (peak systolic velocity >300 cm/s) was considered significant and was followed by arteriography and revision when appropriate.
Definitions
CLI was defined as tissue loss/gangrene and rest pain lasting >2 weeks, in accordance with TASC guidelines.
2 CLI was associated with ankle pressure (<50 mmHg for rest pain; <70 mmHg for tissue loss) or toe pressure (<30 mmHg for rest pain; <50 mmHg for tissue loss). When these measurements could not be obtained because of intractable rest pain or a non-compressible artery secondary to severe calcification, the SPP was measured, and an SPP <40 mmHg was defined as indicative of a critically ischaemic limb. 7 Coronary artery disease (CAD) was defined as a history of any revascularisation of the coronary arteries. Cerebrovascular disease (CVD) was defined as a history of stroke, cerebral haemorrhage, and/or any revascularisation of the carotid arteries. Diabetes mellitus (DM) was diagnosed in patients who were taking hypoglycaemic drugs or self-injected insulin. Ambulatory status was defined as the patient's functional status immediately prior to surgery. Non-ambulatory status was defined as wheelchair bound or bedridden status, and included patients who were able to walk with a cane or by themselves pre-operatively but who later could not walk owing to ischaemic toe or foot lesions. Major amputation included amputation above the ankle. With regard to non-ambulatory status, this was a retrospective study based on the database or medical records, which were occasionally unclear regarding what caused the patients' non-ambulatory status. Certain patients might have suffered from CLI in the diseased limb for a long time or had undergone prior contralateral amputation and were not able to walk by themselves at surgery. Others might have been non-ambulatory because of co-morbidities, such as stroke, spinal disease, and so on. IBG for patients with bedridden status due to neurogenic deficits was not performed. Such patients usually received primary amputation. However, for some of the wheelchair bound patients, the preservation of the foot was less difficult; thereafter, salvage of the diseased limb was attempted.
Survival data were obtained from the outpatient clinic follow-up contacts.
Clinical end points
The end points of the present study were peri-operative death (30-day mortality); AFS; and freedom from MALE, which were defined as an above ankle amputation of the index limb or major re-intervention. These outcomes combined life and limb prognoses. Overall survival and the limb salvage rate were also assessed. 8 
Statistical analysis
Values are expressed as mean AE SD. The baseline characteristics of the patients were compared using the t test or the ManneWhitney test, where appropriate, for continuous data, and the chi-square test or Fisher's exact test was utilised for categorical data. A logistic regression model was used for multivariate analysis to determine the factors predictive of 30-day mortality. Additionally, cumulative event rates were estimated using KaplaneMeier survival curves, and Cox multivariate regression analysis was used to determine the predictors of medium-term clinical outcomes (AFS, freedom from MALE, limb salvage, and survival). Any covariates with p-values <.10 in the univariate analysis were assessed by multivariate analysis. A p-value <.05 was considered significant. The statistical analyses were performed using SPSS version 21 (IBM, Armonk, NY, USA).
RESULTS
Patient characteristics
The overall characteristics of the dialysis dependent patients with CLI who underwent de novo IBG are shown in Table 1 . The rate of non-ambulatory patients was 35%. In total, 57 (64%) patients had DM, 61 (69%) had CAD, and 30 (34%) had CVD. Among the group, 89% were Fontaine class IV. Moreover, the mean preoperative ABI and SPP were 0.54 AE 0.35 and 22 AE 12 mmHg, respectively. Table 2 summarises the details of the bypass surgery. Concerning revascularisation in aortoiliac lesions, EVT was performed in 16 patients (18 limbs), whereas bypass surgery was not performed.
Surgical procedures
The inflow vessel was the common femoral artery in 37 limbs, the superficial femoral artery in 14 limbs, the above knee (AK) popliteal artery in 22 limbs, and the below knee (BK) popliteal artery in 39 limbs. The outflow target vessel was the popliteal artery in 14 limbs (AK ¼ 9; BK ¼ 5), the anterior tibial in 41, the posterior tibial in 18, the peroneal in two, the dorsalis pedis in 32, and the plantar artery in five limbs. Many of the cases had poor runoff, and the mean value of the Rutherford runoff score was 8.4. 
30-day mortality and morbidity
The cases with 30-day mortality are listed in Table 3 . Eight (9%) patients died within 30 days of de novo bypass grafting, two of whom died suddenly owing to severe aortic valve stenosis. Table 4 summarises the details of the 30 day postoperative complications, including those associated with six grafts, two of which became infected, one of which developed bleeding from the anastomosis (<24 hours), and one of which became occluded. Acute coronary syndrome occurred in three (3%) cases, and stroke occurred in two (2%).
After the univariate analysis, an ejection fraction (EF) <40% and a serum albumin level (Alb) <3.0 g/dL were identified as pre-operative factors with a p-value <.10. Thereafter, a logistic regression analysis of these factors was performed. The results of the multivariate analysis showed that an EF <40% was an independent risk factor for 30-day mortality (hazard ratio [HR] 5.57, 95% confidence interval [CI] 1.16e26.83; p ¼ .03).
Medium-term outcomes
The mean follow up duration was 418 AE 345 days. During this period, several re-interventions were performed. Endovascular treatment was administered for vein grafts in five cases, for crural arteries in two, and for femoropopliteal arteries in two. Patch plasty of vein grafts was performed in seven cases, and bypasses were re-performed in three.
The primary patency was 66% and 58% at 1 and 2 years, respectively, and the assisted primary patency was 79% and 77% at 1 and 2 years, respectively. Additionally, the secondary patency was 81% and 81% at 1 and 2 years, respectively.
AFS is shown in Fig. 1A , with values of 64% and 43% at 1 and 2 years, respectively. The results of the multivariate Cox proportional hazard regression analysis of AFS are shown in Supplementary Table S1 . Non-ambulatory status (HR 3.04, 95% CI 1.59e5.82; p < .01) was negatively associated with AFS.
The rates of freedom from MALE were 81% and 77% at 1 and 2 years, respectively ( Fig. 1B; Supplementary Table S2 ). The only predictor of MALE was non-ambulatory status (HR 4.98, 95% CI 1.91e12.96; p < .01).
The overall limb salvage rates were 89% and 85% at 1 and 2 years, respectively (Fig. 1C) . Twelve legs were amputated, of which five legs (AK ¼ 1; BK ¼ 4) were amputated owing to widespread infection, although their bypass grafts were patent. The single regression analysis results for limb salvage were Rutherford category 6 and non-ambulatory status. Multivariate analysis of limb salvage confirmed non-ambulatory status as a predictor (HR 5.18, 95% CI 1.47e18.30; p ¼ .01). Overall survival was 68% and 50% at 1 and 2 years, respectively (Fig. 1D ). In total, 38 patients died during the follow up period (3e1,110 days) from the following causes: respiratory disease (n ¼ 8), cardiovascular disease (n ¼ 6), sepsis (n ¼ 4), bowel ischaemia (n ¼ 3), stroke (n ¼ 2), other causes (n ¼ 6), and unknown causes (n ¼ 9). The results of the single regression analysis for survival were Fontaine classification IV, Alb <3.0 g/dL, an EF <40%, and non-ambulatory status with a p-value <. 10 These clinical outcomes and their predictors are summarised in Table 5 .
DISCUSSION
The current study presents consecutive patients with CLI who underwent de novo IBG at a single vascular centre in Japan. Many studies including dialysis dependent patients with CLI have reported medium-term results. In addition, several reports have focused on patients receiving haemodialysis. 10, 11 However, these studies had small to moderate sample sizes. As far as is known, the present study is the first and largest to demonstrate freedom from MALE after IBG in a haemodialysis only cohort.
In this study, the 30 day mortality after IBG was 9% for patients receiving haemodialysis. In a meta-analysis, Albers et al. reported peri-operative mortality of 8.8%. 12 Biancari et al. also reported high peri-operative mortality rates (3e17%). 14 Moreover, several studies of EVT showed a mortality rate of Figure 1 . (A) Amputation free survival (AFS) after infrainguinal bypass grafting for 89 patients with critical limb ischaemia (CLI). AFS was 64 AE 5%, 43 AE 6%, and 33 AE 8% at 1, 2, and 3 years, respectively. (B) Freedom from major adverse limb events (MALE) after infrainguinal bypass grafting for 112 cases of CLI. Overall freedom from MALE was 81 AE 4%, 77 AE 5%, and 74 AE 2% at 1, 2, and 3 years, respectively. (C) Limb salvage rate (LS) after infrainguinal bypass grafting for 112 patients with CLI. LS was 89 AE 4%, 85 AE 4%, and 33 AE 8% at 1, 2, and 3 years, respectively. (D) Overall survival (OS) rate after infrainguinal bypass grafting for 89 cases of CLI. OS was 68 AE 5%, 50 AE 7%, and 45 AE 8% at 1, 2, and 3 years, respectively.
3.3e8.3% in patients receiving haemodialysis. 12, 13 The results of the present study are comparable with these past findings. In addition, this study demonstrates that an independent predictor of 30 day mortality is an EF <40%. Biancari et al. demonstrated that diabetes, CAD, foot gangrene, and urgent operations were also independent predictors of 30 day mortality and/or major lower-limb amputation.
14 Several small to moderate sized (n ¼ 20e121) studies of IBG to treat CLI in patients receiving haemodialysis have demonstrated 1 and 2 year limb salvage rates of 64e88% and 56e85%, respectively. Moreover, these studies have shown that the overall survival rates at 1 and 2 years were 50e78% and 23e45%, respectively. 15e20 The results presented here show that the limb salvage rates were 89% and 85% at 1 and 2 years, respectively, and that survival was 68% and 50% at 1 and 2 years, respectively. These data are equivalent to those reported in other studies. Recently, Nakano et al. reported the outcomes of EVT to treat CLI in Japanese patients on haemodialysis. 13 The study showed that the limb salvage rates at 1 and 3 years were 81% and 77%, respectively, and that the survival rates at 1 and 3 years were 72% and 47%, respectively. The patient profiles and limb selection differed between the cohort of Nakano et al. and that presented here, 13 and the limb salvage rate in the present study was slightly higher than that of the cohort of Nakano et al. 13 However, neither the study of Nakano et al. nor the present one evaluated wound healing time after revascularisation, which might have caused the difference in limb salvage rates. Several studies have concluded that endovascular techniques that use a minimally invasive approach should be considered as an alternative to bypass grafting. 21, 22 However, the final results of the BASIL trial demonstrated that the outcomes of bypass surgery after failed EVT were worse than those of bypass surgery performed as the first line treatment, suggesting that EVT should not always be the first line treatment. 5 Recently, a working group under the auspices of the Society for Vascular Surgery used pooled data from the PREVENT III, BASIL, and Circulase studies to identify expected outcomes for vein bypass surgery as the relevant standard for comparing new devices. This group endorsed a set of three safety and six efficacy objective performance goals (OPGs) for CLI based on the pooled data from these surgical controls. 8 The group suggested MALE and AFS, among others, and reported that the OPGs were AFS, freedom from MALE, limb salvage, and survival, with rates of 71%, 71%, 84%, and 80%, respectively. In the present study, 1 year values for AFS (64%), freedom from MALE (81%), limb salvage (89%), and survival (68%) were obtained, with poorer AFS and survival than in a study by Conte. 8 However, the three randomised controlled trials from which the OPGs were derived did not include patients with CLI receiving haemodialysis. A meta-analysis of the results of revascularisation using vein grafts revealed that the 2 year amputation free rate for the lower limb was 75% and that the survival rate was 54% in patients on dialysis. 12 These values were comparable to the medium-term results of the present study. Conte also suggested using MALE þ perioperative death (POD) as the primary efficacy end point for single arm trials for CLI. 8 However, patients receiving haemodialysis are high risk candidates for postoperative complications and 30 day mortality.
14 Therefore, an attempt was made to identify separately 30 day mortality (POD) and freedom from MALE.
Little information has been available on the predictors of medium or long-term outcomes in patients receiving haemodialysis. In our study, hypoalbuminaemia was one of the independent risk factors for survival. When performing infrainguinal revascularisation (including EVT) to treat CLI in patients receiving haemodialysis, Biancari et al. reported that hypoalbuminaemia was a predictor of survival. 16 Additionally, Azuma et al. studied 228 patients with CLI, including non-haemodialysis patients, and showed that hypoalbuminaemia was an independent risk factor for clinical failure after distal bypass. 23 Hypoalbuminaemia is also associated with poor nutritional status, chronic inflammation, and poor clinical outcomes, including mortality, in patients receiving dialysis. 24 In the patients in the present study, the rate of statin use was only 12%. Statins have certain long-term benefits in patients with PAD, 2 and the pleiotropic effects and cardiovascular benefits of statin therapy have been well established. 25 However, under the Japanese National Health Insurance system, statins are only permitted to be prescribed for patients with hyperlipidaemia (low-density lipoprotein >140 mg/dL, high-density lipoprotein <40 mg/dL, triglycerides >150 mg/dL), and hyperlipidaemia was noted in only 15% of the patients in the present study. In other studies, hyperlipidaemia has been reported in 5e23% of patients. 13, 16, 26 Other reports have shown that myocardial infarction, congestive heart failure, and CAD are predictors of survival. 27, 28 The present study showed that non-ambulatory status was one of the negative predictors of limb salvage, AFS, and survival. Goodney et al. also reported that nonambulatory status was a negative factor for major amputation after bypass surgery in patients with CLI and claudication. 29 Several studies have additionally reported on the predictors of the clinical outcomes of CLI after EVT in the dialysis population. 21 non-ambulatory status was a predictor not only of survival, but also of limb salvage after infrapopliteal angioplasty in patients receiving dialysis. 30 This factor was one of the significant risk factors for survival in both the surgical and the endovascular treatment populations. However, in this study, EVT was considered as the first line therapy for patients with CLI with both non-ambulatory status and hypoalbuminaemia because it is safe and less invasive, and because of its initial clinical success rate. 13, 30 Because the benefits of surgical revascularisation might be modest for patients with ESRD, several authors have recognised a role for primary amputation when tissue loss is extensive. 31 However, the authors of the present study believe that revascularisation in patients receiving haemodialysis with CLI is necessary whenever feasible for the maintenance of quality of life. Risk stratification should be performed to improve both the safety and the efficacy of IBG, and to determine the optimal revascularisation treatment, whether IBG or EVT.
This study has several limitations. Firstly, it was a retrospective, single-centre study. Larger multicentre studies are warranted to corroborate the findings. Secondly, the choices of procedure and medications depended on the surgeon. These choices might have affected clinical outcomes. Thirdly, wound healing time was not investigated because not all of the medical charts were recorded precisely. However, it is still believed that bypass grafting offers several advantages over EVT and that this comparison is an important topic for future studies.
CONCLUSION
The pathophysiology of patients with CLI receiving haemodialysis can be characterised as follows: (1) Patients enjoyed satisfactory freedom from MALE and limb salvage, but survival and AFS were significantly less than those reported for IBG in patients with CLI who did not also suffer from dialysis; (2) patients with an EF <40%, low Alb (<3.0 mg/dL), or non-ambulatory status have particularly poor clinical outcomes after IBG.
